Depth of response corresponded to overall survival and time to next treatment in real-world patients with relapsed/refractory multiple myeloma.
Patients who did not have immune dysregulation had higher overall survival compared with patients who had immune dysregulation.
Bortezomib-based induction therapy is the current standard of care for patients with multiple myeloma, but thalidomide is a promising contender.
Cytarabine as a Chemotherapeutic Agent for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Intermediate-dose cytarabine has been demonstrated to have high efficacy as a chemomobilization agent.
Partial remission or better was observed in 85% of evaluable patients who received pomalidomide, cyclophosphamide, and dexamethasone.
PET-CT Scans May Be Useful in Predicting Prognosis in Patients With Newly Diagnosed Multiple Myeloma
PET-CT scans can reveal abnormalities such as bony lesions and extramedullary disease in patients with multiple myeloma.
First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.
The manufacturing approach yielded therapeutic doses of engineered T cells with activity against NKG2D ligands in acute myeloid leukemia and multiple myeloma.
An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.
Previous studies showed that elotuzumab plus lenalidomide and dexamethasone improved progression-free survival and response rates, but its impact on patient-reported outcomes is unknown.
Researchers found that clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic in patients with multiple myeloma.
Researchers investigated cancer-related fatigue in 16 patients with multiple myeloma who were treated with bortezomib, lenalidomide, or thalidomide.
Abdominal adiposity was determined to be a better predictor of risk for hematological malignancies compared with BMI.
There is paucity of comparative and efficacy information on novel agents used as frontline induction therapies in multiple myeloma.
Levels of hemoglobin, combined with ESR, PV, and calcium values, were determined to be the blood parameters with the most diagnostic value in multiple myeloma.
High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.
Drug coverage status influenced the treatments that were selected for Medicare beneficiaries with myeloma and, consequently, their overall survival.